Ad26.COV2-S Vaccine Seems Safe, Immunogenic for SARS-CoV-2
Neutralizing antibodies detected in 90 percent or more of all participants on day 29 after the first vaccine dose.
Infectious Disease
Negative COVID-19 Test to Be Required for People Flying to US
Passengers without proof of a negative test will not be allowed to board flights to America
FDA Fast Tracks Brilacidin for COVID-19 Treatment
Brilacidin is a first-in-class host defense protein mimetic.
Phase 3 Study Evaluating Ravulizumab for COVID-19 Paused
The open-label, controlled study enrolled adults hospitalized with COVID-19 and severe pneumonia, acute lung injury or acute respiratory distress syndrome.
HIV Patient’s Detectable Viremia Linked to ART-Supplement Interaction
Prior to pregnancy, her viral load had been undetectable for more than 2 years.
Perception of Not Returning to Full Health Common After COVID-19
47 percent experience fatigue, with no correlation between any measures of persistent disease and initial disease severity
Pfizer-BioNTech COVID-19 Vaccine Elicits Response Against Key Mutation
The study was conducted by Pfizer and the University of Texas Medical Branch.
Early High-Titer Plasma Reduces Progression of COVID-19
Early administration of high-titer convalescent plasma against SARS-CoV-2 reduces progression in mildly ill older adults
Use of Direct Acting Antivirals With Potent Inducers Examined in Case Series
While DAAs have improved the treatment of chronic HCV infection by eliciting higher rates of sustained virologic response, they also interact with a number of agents that could potentially limit their effectiveness.
Majority of SARS-CoV-2 Transmission Due to Asymptomatic Individuals
In base case of modeling study, 59 percent of transmission attributed to presymptomatic and asymptomatic individuals
